Valuation: Regeneron Pharmaceuticals, Inc.

Market Cap 96.11B 87.58B 80.97B 73.07B 138B 8,982B 143B 976B 386B 4,847B 361B 353B 15,312B P/E 2026 *
16.2x
P/E 2027 * 15.4x
Enterprise Value 88.94B 81.05B 74.93B 67.62B 127B 8,312B 133B 903B 357B 4,486B 334B 327B 14,170B EV / Sales 2026 *
4.73x
EV / Sales 2027 * 4.14x
Free-Float
72.51%
Yield 2026 *
0.39%
Yield 2027 * 0.42%
1 day-1.28%
1 week-1.45%
Current month+1.90%
1 month+20.91%
3 months+16.70%
6 months+50.16%
Current year+22.50%
1 week 942
Extreme 942
981.55
1 month 780.83
Extreme 780.83
991.73
Current year 591.52
Extreme 591.52
991.73
1 year 591.52
Extreme 591.52
991.73
3 years 476.49
Extreme 476.4869
1,211.2
5 years 476.49
Extreme 476.4869
1,211.2
10 years 271.37
Extreme 271.37
1,211.2
Manager TitleAgeSince
President 66 01/01/2001
Chief Executive Officer 73 08/01/1988
Director of Finance/CFO 55 05/02/2024
Director TitleAgeSince
Chairman 73 09/06/2023
Director/Board Member 85 01/06/1991
Director/Board Member 76 08/01/1988
Date Insider Type Main position Quantity % Market Cap. Importance
4/11/26 Exercice

SVP Controller

11,828 0.0117%
3/11/26 Exercice

Director

22,317 0.0221%
3/11/26 Don

Chief Technology Officer

-1,054 0.0010%
Change 5-day change 1-year change 3-year change Capi.($)
-1.28%-1.45%+30.36%+17.95% 96.11B
-2.32%-3.79%+34.24%+131.38% 1,261B
-2.15%-2.75%+36.35%+81.91% 671B
-2.33%-3.04%+22.29%+106.79% 518B
-0.69%+0.40%+40.46%+69.78% 387B
-3.90%-6.39%+42.88%+34.18% 353B
-1.35%-2.23%+24.30%+56.34% 300B
-1.13%-1.71%+0.40%+33.00% 283B
-3.07%-5.17%+29.04%+67.28% 248B
-0.75%-0.44%+32.87%+122.34% 211B
Average -1.45%+0.02%+29.32%+72.10% 433B
Weighted average by Cap. -1.71%-0.46%+31.05%+89.06%

Financials

2026 *2027 *
Net sales 18.81B 17.15B 15.85B 14.31B 26.95B 1,758B 28.04B 191B 75.59B 949B 70.57B 69.1B 2,998B 20.17B 18.38B 16.99B 15.33B 28.88B 1,885B 30.06B 205B 81.02B 1,017B 75.65B 74.07B 3,213B
Net income 6.43B 5.86B 5.41B 4.89B 9.2B 601B 9.58B 65.24B 25.82B 324B 24.1B 23.6B 1,024B 6.56B 5.98B 5.53B 4.99B 9.39B 613B 9.78B 66.59B 26.35B 331B 24.6B 24.09B 1,045B
Net Debt -7.17B -6.53B -6.04B -5.45B -10.27B -670B -10.68B -72.77B -28.8B -362B -26.89B -26.33B -1,142B -12.52B -11.41B -10.55B -9.52B -17.93B -1,170B -18.66B -127B -50.29B -631B -46.95B -45.97B -1,994B
Projected Income Statement - Annual - Regeneron Pharmaceuticals, Inc.
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.
Employees
15,410
Date Price Change Volume
17/11/26 USD 957.76 +0.56% 933,408
16/11/26 USD 952.40 -0.32% 700,861
13/11/26 USD 955.47 +0.45% 1,165,717
12/11/26 USD 951.19 -0.86% 1,211,308
11/11/26 USD 959.41 +4.73% 1,233,521
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Regeneron Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
957.76USD
Average target price
990.81USD
Spread / Average Target
+3.45%
  1. Stock Market
  2. Stocks
  3. REGN Stock